Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

AnaptysBio’s consensus price target implies 38.8% upside, and the article highlights an upward trend in earnings estimate revisions as a potential near-term catalyst. While it notes that price targets are not especially effective on their own, the improving estimate trend supports a mildly constructive outlook for the stock.

Analysis

AnaptysBio’s consensus price target implies 38.8% upside, and the article highlights an upward trend in earnings estimate revisions as a potential near-term catalyst. While it notes that price targets are not especially effective on their own, the improving estimate trend supports a mildly constructive outlook for the stock.